Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cabaletta Bio Inc (NQ: CABA )

12.96 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11
Open 12.96
Bid (Size) 12.56 (1)
Ask (Size) 14.91 (2)
Prev. Close 12.96
Today's Range 12.96 - 12.96
52wk Range 7.690 - 26.35
Shares Outstanding 31,355,723
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023
CABA stock results show that Cabaletta Bio missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Recap: Cabaletta Bio Q4 Earnings
Via Benzinga

Performance

YTD
-41.52%
-41.52%
1 Month
-22.81%
-22.81%
3 Month
-36.78%
-36.78%
6 Month
+1.17%
+1.17%
1 Year
+60.40%
+60.40%

More News

Read More
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 12/8
Via Investor Brand Network
Analyst Ratings for Cabaletta Bio
Via Benzinga
Where Cabaletta Bio Stands With Analysts
Via Benzinga
Cabaletta Bio Inc. (NASDAQ: CABA) is a Stock Spotlight on 11/9
Via Investor Brand Network
Cramer: This REIT Is 'A Little Too Dicey'; As For Marathon Digital, 'Own The Pure'
Via Benzinga
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio: Q3 Earnings Insights
Via Benzinga
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Cabaletta Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Verint Reports Strong Earnings, Joins Semtech, Alphabet And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Leslie's Posts Weak Earnings, Joins Las Vegas Sands, Verve Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Cabaletta Bio
Via GlobeNewswire
Crude Oil Surges 2%; Tharimmune Shares Plummet
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Cantor Fitzgerald Maintains Overweight Rating for Cabaletta Bio: Here's What You Need To Know
Via Benzinga
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
From Cellares
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.